We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
-20.84%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$37.7B
AUM Growth
-$10.7B
(-22%)
Cap. Flow
+$89.7M
Cap. Flow
% of AUM
0.24%
Top 10 Holdings %
Top 10 Hldgs %
24%
Holding
1,459
New
89
Increased
670
Reduced
570
Closed
85
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kinross Gold
KGC
|
+$295M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$97.8M |
| 3 |
Rockwell Automation
ROK
|
+$97.4M |
| 4 |
TransUnion
TRU
|
+$95.8M |
| 5 |
Adobe
ADBE
|
+$93.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$158M |
| 2 |
Cheniere Energy
LNG
|
+$123M |
| 3 |
Lockheed Martin
LMT
|
+$118M |
| 4 |
AZPN
ASPEN TECHNOLOGY INC
AZPN
|
+$117M |
| 5 |
Halliburton
HAL
|
+$108M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 34.08% |
| 2 | Technology | 25.82% |
| 3 | Energy | 9.46% |
| 4 | Healthcare | 7.07% |
| 5 | Financials | 5.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Kirby Corp
KEX
$7.76B
| $29M | 0.08% |
476,940
-29,340
| -6% | -$1.91M |
|
202
Novartis
NVS
$297B
| $29M | 0.08% |
343,204
+123,649
| +56% | +$10.8M |
|
|
NVO
203
Novo Nordisk
NVO
$220B
| $28.8M | 0.08% |
517,060
+175,086
| +51% | +$9.72M |
|
204
Public Storage
PSA
$60.5B
| $28.6M | 0.08% |
91,426
-5,833
| -6% | -$2.02M |
|
205
Cencora
COR
$60.5B
| $28.5M | 0.08% |
201,173
+38,704
| +24% | +$5.92M |
|
206
Sanofi
SNY
$105B
| $28.4M | 0.08% |
566,931
+219,580
| +63% | +$11.7M |
|
207
Moderna
MRNA
$22.1B
| $28M | 0.07% |
196,138
-102,523
| -34% | -$14.7M |
|
208
Takeda Pharmaceutical
TAK
$55.7B
| $27.9M | 0.07% |
1,989,772
+862,502
| +77% | +$12.3M |
|
209
Toro Company
TTC
$9.01B
| $27.1M | 0.07% |
357,500
+90,489
| +34% | +$7.34M |
|
210
Main Street Capital
MAIN
$5B
| $27M | 0.07% |
699,836
-79,056
| -10% | -$3.09M |
|
211
GSK
GSK
$104B
| $26.6M | 0.07% |
488,346
+175,474
| +56% | +$9.69M |
|
212
VanEck Merk Gold Trust
OUNZ
$2.53B
| $26.5M | 0.07% |
1,513,767
+1,018,769
| +206% | +$18.5M |
|
|
NEE.PRQ
213
DELISTED
NextEra Energy, Inc. 6.219% Corporate Units
NEE.PRQ
| $26.2M | 0.07% |
533,590
+79,726
| +18% | +$3.91M |
|
|
CTLT
214
DELISTED
CATALENT, INC.
CTLT
| $26.1M | 0.07% |
243,445
+80,141
| +49% | +$8.16M |
|
215
Bilibili
BILI
$7.47B
| $25.7M | 0.07% |
1,004,791
-110,520
| -10% | -$2.66M |
|
216
Accenture
ACN
$94.3B
| $25.4M | 0.07% |
91,358
-1,093
| -1% | -$328K |
|
|
SGEN
217
DELISTED
Seagen Inc. Common Stock
SGEN
| $25.2M | 0.07% |
142,494
+9,533
| +7% | +$1.37M |
|
218
Golub Capital BDC
GBDC
$3.36B
| $25M | 0.07% |
1,931,033
-179,873
| -9% | -$2.57M |
|
219
Blackstone Secured Lending
BXSL
$5.35B
| $25M | 0.07% |
+1,057,237
| New | +$27.4M |
|
220
Helix Energy Solutions
HLX
$1.42B
| $24.4M | 0.06% |
7,877,907
+472,058
| +6% | +$2.04M |
|
|
SOLN
221
DELISTED
The Southern Company
SOLN
| $24.4M | 0.06% |
460,223
+68,765
| +18% | +$3.78M |
|
222
Teva Pharmaceuticals
TEVA
$36.2B
| $24.2M | 0.06% |
3,213,734
+1,324,951
| +70% | +$11.5M |
|
223
Viatris
VTRS
$20.5B
| $24.1M | 0.06% |
2,297,172
+719,175
| +46% | +$7.88M |
|
224
Hercules Capital
HTGC
$2.95B
| $24M | 0.06% |
1,780,910
-91,012
| -5% | -$1.42M |
|
225
Prospect Capital
PSEC
$1.12B
| $24M | 0.06% |
3,431,123
-502,834
| -13% | -$3.86M |
|
Similar funds
DAM
VanEck Associates's Q2 2022 Portfolio in Review
As of Q2 2022, VanEck Associates held 1,459 positions worth $37.7B, down 22% from $48.5B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
VanEck Associates's Q2 2022 filing shows 89 new, 670 increased, 570 reduced and 85 closed positions. Its largest new stake was Blackstone Secured Lending: 1,057,237 shares worth $25M. The largest sale was SLB Ltd, an estimated $158M.
By sector, the portfolio is most concentrated in Materials at 34% of assets, down from 37% a quarter earlier, followed by Technology and Energy.
- VanEck Associates's largest Q2 2022 buy was Blackstone Secured Lending: 1,057,237 shares worth $25M.
- VanEck Associates added most to Kinross Gold in Q2 2022, an estimated $295M increase.
- VanEck Associates's biggest Q2 2022 reduction was SLB Ltd, cutting an estimated $158M.
- VanEck Associates fully exited ASPEN TECHNOLOGY INC in Q2 2022, selling an estimated $117M.
- VanEck Associates's ten largest holdings make up 24% of its $37.7B portfolio in Q2 2022.
- VanEck Associates opened 89 new positions and closed 85 in Q2 2022.
- VanEck Associates's portfolio value fell 22% quarter-over-quarter to $37.7B.
Based on VanEck Associates's 13F filing for Q2 2022, filed 3 Aug 2022.